CAS:433922-67-9
纯度:98.64%
分子量:2309.53
Formula:C111H149N27O28
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:
Sealed storage, away from moisture and light, under nitrogen
Powder | -80°C | 2 years |
---|---|---|
-20°C | 1 year |
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
产品活性:Edratide (TV 4710) 是一种由 19 个氨基酸组成的合成肽,它基于人类抗 DNA 抗体的互补决定区 1 (CDR1),表达主要独特型 16/6 Id。Edratide 降低细胞凋亡 (apoptosis) (Apoptosis) 率并下调 caspase-8 和 caspase-3,上调 Bcl-xL。Edratide 具有研究系统性红斑狼疮 (SLE) 的潜力。
生物活性:Edratide (TV 4710)是一种基于人抗dna抗体的互补决定区1 (CDR1)的19个氨基酸的合成肽,表达一个主要的独特型16/6 Id。Edratide降低细胞凋亡率(apoptosis),下调caspase-8和caspase-3,上调Bcl-xL。Edratide在系统性红斑狼疮(SLE)的研究中具有潜力[1][2][3]。
体内:
乙拉肽(20-50µg;南卡罗来纳州。每周一次,持续10周)通过调节基因表达对SLE产生有益作用[2]。
艾拉替特(50 μg/只;南卡罗来纳州。(10周)降低SLE小鼠的凋亡率,下调caspase-8和caspase-3,上调Bcl-xL[3]。
参考文献:
[1]. Urowitz MB, et al. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. Lupus Sci Med. 2015 Aug 11;2(1):e000104.
[2]. Elmann A, et al. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations. Arthritis Rheum. 2007 Jul;56(7):2371-81.
[3]. Sharabi A, et al. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol. 2007 Oct 15;179(8):4979-87.